|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
To assess potential differences between the efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab, in patients with vs without prior myocardial infarction (MI)/ischemic stroke.
|
31076261 |
2020 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
Furthermore, clinical trials with PCSK9 inhibitors demonstrate that reductions in atherosclerotic cardiovascular disease events are more effective in patients with recent myocardial infarction, multiple myocardial infarctions, multivessel coronary artery disease, and lower extremity arterial disease.
|
30702994 |
2019 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
In contrast, PCSK9 inhibition was associated with reductions in myocardial infarction (OR 0.80, 95% CI 0.71 to 0.91; p <0.0001), stroke (OR 0.75, 95% CI 0.65 to 0.85; p <0.0001), and coronary revascularization (OR 0.82, 95% CI 0.77 to 0.88; p <0.0001).
|
31679643 |
2019 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
Both myocardial infarction and stroke were significantly reduced following the treatment with an anti-PCSK9 mAb.
|
30926528 |
2019 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
For secondary endpoints, proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK) plus statin (PCSK/ST) significantly reduced the risk of non-fatal MI (RR 0.82, 95% CI 0.72-0.93, <i>p</i> = 0.003), stroke (RR 0.74, 95% CI 0.65-0.85, <i>p</i> < 0.001), coronary revascularization (RR 0.84, 95% CI 0.75-0.94, <i>p</i> = 0.003) compared to ST.
|
31191304 |
2019 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Proprotein convertase subtilisin-kexin type 9 inhibitors were associated with lower risk of MI (1.49 vs. 1.93 per 100 patient-year; RR 0.80, 95% CI 0.74-0.86; I2 = 0%; P < 0.0001), ischaemic stroke (0.44 vs. 0.58 per 100 patient-year; RR 0.78, 95% CI 0.67-0.89; I2 = 0%; P = 0.0005), and coronary revascularization (2.16 vs. 2.64 per 100 patient-year; RR 0.83, 95% CI 0.78-0.89; I2 = 0%; P < 0.0001), compared with the control group.
|
31270529 |
2019 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This study enrolled PMI patients (n = 225) and detected the mutations in their FH-associated genes (LDLR, APOB, PCSK9, LDLRAP1) by Sanger sequencing.
|
30971288 |
2019 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95% CI 0.42; 0.68), compared to a PCSK9 inhibitor effect of 0.90 (95% CI 0.86; 0.93).
|
31664920 |
2019 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
This study demonstrated that PCSK9 inhibitors could significantly reduce the risk of MACE, non-fatal MI and stroke.
|
30842207 |
2019 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin-kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI.
|
31121022 |
2019 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibodies, reduce low-density lipoprotein cholesterol levels and improve outcomes of myocardial infarction and stroke.
|
30729307 |
2019 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
The individual estimated lifetime benefit from PCSK9 inhibition in patients with stable CAD on high-dose statin varied from <6 to ≥12 months free of stroke or MI.
|
29622600 |
2018 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In good agreement with previous studies in patients with familial hypercholesterolaemia, our study in the Japanese general population showed that rare variants in LDLR and PCSK9 were associated with the onset age of MI by altering LDL-cholesterol levels.
|
29802317 |
2018 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
Results In network meta-analysis of 189,116 patients, PCSK9 inhibitors were ranked as the best treatment for prevention of major adverse cardiovascular events (Surface Under Cumulative Ranking Curve (SUCRA), 85%), myocardial infarction (SUCRA, 84%) and stroke (SUCRA, 80%).
|
29569492 |
2018 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
In adjusted Cox analysis, plasma PCSK9 was associated, independently of classic risk factors, with the incidence of major CV events (hazard ratio [HR] for 1-unit increase of log[PCSK9] 1.28 [95% confidence interval {CI} 1.06-1.55]), the incidence of MI (HR 1.66 [95% CI 1.05-2.63]), and the incidence of all CV events (HR 1.22 [95% CI 1.04-1.44]), but not with CV death.
|
29205760 |
2018 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab significantly reduced major vascular events in patients with stable atherosclerotic cardiovascular disease, including patients with prior myocardial infarction (MI).
|
29626068 |
2018 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Similar results were observed when we examined the association between docosahexaenoic acid, which is one type of LC n-3 PUFA, and nonfatal MI risk (<i>P</i>-interaction = 0.003).<b>Conclusion:</b> LC n-3 PUFA intake is associated with a lower risk of nonfatal MI in C-allele carriers of <i>PCSK9</i> rs11206510 (<i>n</i> = 799) but not in non-C-allele carriers (<i>n</i> = 3188).
|
28330911 |
2017 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
PCSK9 R46L carriers vs noncarriers had an age- and sex-adjusted odds ratio of 0.64 (95% confidence interval, 0.44-0.95) for aortic valve stenosis, 0.77 (0.65-0.92) for myocardial infarction, and 0.76 (0.64-0.89) for aortic valve stenosis or myocardial infarction.
|
27218270 |
2016 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Except for a few examples (eg, PCSK9), the role of low-frequency genetic variation (minor allele frequency [MAF]) ≈0.1%-5% on MI/coronary artery disease predisposition has not been extensively investigated.
|
22923420 |
2012 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population.
|
20699424 |
2010 |
|
Myocardial Infarction
|
0.200 |
GeneticVariation
|
disease |
LHGDN |
A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction.
|
18499582 |
2008 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
BEFREE |
We noted that PCSK9 46L was associated with tendency for protection from myocardial infarction but not stroke suggesting a difference in the effect on susceptibility to these disorders.
|
18343176 |
2008 |
|
Myocardial Infarction
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Polymorphisms in myocyte enhancer factor 2A, a transcription factor, tumor necrosis factor (ligand) superfamily, member 4, the OX40 ligand, and proprotein convertase subtilisin/kexin type 9, which affect low-density lipoprotein levels, have all been associated with an altered risk of coronary artery disease and myocardial infarction.
|
16943719 |
2006 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|